| Identification | Back Directory | [Name]
[R-(R*,R*)]-2-(1-Azabicyclo[2.2.2]oct-3-yl)-2,3,3a,4,5,6-hexahydro-1H-benz[de]isoquinolin-1-one | [CAS]
149653-99-6 | [Synonyms]
CID 148211
Palonosetron USP/EP/BP
(R)-2-((R)-quinuclidin-3-yl)-2,3,3a,4,5,6-hexahydro-1H-benzo[de] isoquinolin-1-one
[r-(r*,r*)]-2-(1-azabicyclo[2.2.2]oct-3-yl)-2,3,3a,4,5,6-hexahydro-1h-benz[de]isoquinolin-1-one
1H-Benz[de]isoquinolin-1-one, 2-(3R)-1-azabicyclo[2.2.2]oct-3-yl-2,3,3a,4,5,6-hexahydro-, (3aR)- | [Molecular Formula]
C19H24N2O | [MOL File]
149653-99-6.mol | [Molecular Weight]
296.41 |
| Hazard Information | Back Directory | [Indications]
Palonosetron is approved by the US FDA for acute and delayed CINV and PONV. | [Biological Activity]
Palonosetron is a highly selective, high-affinity 5-HT3 receptor antagonist. Due to its structural difference from the first-generation 5-HT3 receptor antagonists, palonosetron has an affinity for the 5-HT3 receptor at least 30 times that of other similar drugs. | [in vitro]
Palonosetron is neither an inhibitor of CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2D6, CYP2E1 and CYP3A4/5 (CYP2C19 not studied) nor does it induce the activity of CYP1A2, CYP2D6 or CYP3A4/5. |
|
|